CARLSBAD, CA--(Marketwire - Aug 30, 2012) - International Stem Cell Corporation (OTCQB: [ ISCO ]) ([ www.internationalstemcell.com ]) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, today announced that the Company will attend and present at the following investor conferences in September.

Wall Street Analyst Forum Investor Conference
Date: Friday, September 7, 2012
Time: 10:35 am ET
Location: Omni Parker House - Boston, MA

Rodman & Renshaw Annual Global Investment Conference
Date: Monday, September 10, 2012
Time: 11:40 am ET
Location: The Waldorf Astoria Hotel, New York, NY

Please contact the conference organizers if you have an interest in attending these conferences or if you would like to arrange a meeting with International Stem Cell's management team. You may also contact Mark McPartland with MZ Group via email [ markmcp@mzgroup.us ] or phone 1-212-301-7130 to arrange a meeting with management.

Additional information of the investor presentations will be available on the investor relations section of the Company's website [ www.internationalstemcell.com ].

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ([ www.lifelinecelltech.com ]), and stem cell-based skin care products through its subsidiary Lifeline Skin Care ([ www.lifelineskincare.com ]). More information is available at [ www.internationalstemcell.com ].

To receive ongoing corporate communications via email, visit: [ http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 ]

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: [ www.facebook.com/InternationalStemCellCorporation ] and [ www.twitter.com/intlstemcell ]

Safe harbor statement

Statements pertaining to anticipated developments, scientific program and clinical development goals and plans, potential sales growth, new products and distribution channels and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.